## Javier Munoz

## List of Publications by Citations

Source: https://exaly.com/author-pdf/9633689/javier-munoz-publications-by-citations.pdf

Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51	2,927	12	<b>52</b>
papers	citations	h-index	g-index
52	4,132 ext. citations	8.3	4.35
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
51	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 2531-2544	59.2	2326
50	Concise review: umbilical cord blood transplantation: past, present, and future. <i>Stem Cells Translational Medicine</i> , <b>2014</b> , 3, 1435-43	6.9	63
49	Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e351-2	2.2	53
48	Erdheim-Chester disease: characteristics and management. <i>Mayo Clinic Proceedings</i> , <b>2014</b> , 89, 985-96	6.4	50
47	Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 362-371	7.1	50
46	STAT3 inhibitors: finding a home in lymphoma and leukemia. <i>Oncologist</i> , <b>2014</b> , 19, 536-44	5.7	48
45	Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 533-47	6.1	46
44	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , <b>2021</b> ,	59.2	45
43	Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8008-8008	2.2	33
42	Androgen receptors beyond prostate cancer: an old marker as a new target. <i>Oncotarget</i> , <b>2015</b> , 6, 592-6	<b>03</b> .3	29
41	Targeted therapy in rare cancersadopting the orphans. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 631-	<b>42</b> 9.4	25
40	Molecular profiling and the reclassification of cancer: divide and conquer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> , 127-34	7.1	20
39	Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Klinhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 368-376	1.9	12
38	Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 167-71	3.5	11
37	Severe lactic acidosis in a patient with metastatic prostate cancer. <i>Journal of Cancer Research and Therapeutics</i> , <b>2011</b> , 7, 201-2	1.2	11
36	Molecular Profiling and the Reclassification of Cancer: Divide and Conquer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> , 33, 127-	134 <sup>1</sup>	11
35	Histiocytic sarcoma of the thyroid. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 531	7.1	9

34	A tale of two histiocytic disorders. <i>Oncologist</i> , <b>2013</b> , 18, 2-4	5.7	9
33	Uumour-induced osteomalaciaU <i>BMJ Case Reports</i> , <b>2012</b> , 2012,	0.9	8
32	Posterior reversible encephalopathy syndrome: more than meets the eye. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e360-3	2.2	8
31	Mucormycosis-associated intracranial hemorrhage. <i>Blood Coagulation and Fibrinolysis</i> , <b>2013</b> , 24, 100-1	1	6
30	The dilemma of inherited dysfibrinogenemia during pregnancy. <i>Blood Coagulation and Fibrinolysis</i> , <b>2012</b> , 23, 775-7	1	6
29	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. <i>Blood Advances</i> , <b>2021</b> ,	7.8	6
28	Epidermal growth factor receptor-induced hirsutism and trichomegaly. <i>Mayo Clinic Proceedings</i> , <b>2011</b> , 86, e50	6.4	5
27	Blastic plasmacytoid dendritic cell neoplasm. American Journal of Hematology, 2012, 87, 710	7.1	4
26	Cytomegalovirus-induced haemophagocytic lymphohistiocytosis syndrome. <i>BMJ Case Reports</i> , <b>2012</b> , 2012,	0.9	4
25	Progression of double-hit lymphoma in the midst of R-hyper CVAD. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 87-8	7.1	3
24	Iron-overload myopathy. International Journal of Hematology, 2011, 94, 503-4	2.3	3
23	Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. <i>Targeted Oncology</i> , <b>2021</b> , 16, 295-308	5	3
22	CNS hyperleukocytosis. <i>Blood</i> , <b>2012</b> , 119, 5953	2.2	2
21	Lymphocytosis: T-cell large granular lymphocyte leukemia. <i>Blood</i> , <b>2012</b> , 120, 1543	2.2	2
20	Basophilic stippling: a lead to the diagnosis. <i>Blood</i> , <b>2011</b> , 118, 5370	2.2	2
19	Antibiotic-refractory sinusitis. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 2399-400	27.4	2
18	Rash in an immunocompromised patient. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 307, 612-3	27.4	2
17	Reactive eosinophilia and thrombosis. <i>Blood</i> , <b>2012</b> , 120, 2785	2.2	1

16	Salmonella-related mycotic aortic aneurysm heralding a diagnosis of multiple myeloma. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 820-1	7.1	1
15	Sister Mary Joseph Id nodule. BMJ Case Reports, 2011, 2011,	0.9	1
14	The Prognostic Implications of Nucleated Red Blood Cells in Myelodysplastic Syndrome. <i>Blood</i> , <b>2011</b> , 118, 5058-5058	2.2	1
13	The Relevance of Increased Tonsil Uptake When Restaging Lymphoma with Positron Emission Tomography. <i>Blood</i> , <b>2010</b> , 116, 3133-3133	2.2	1
12	Zanubrutinib in lymphoproliferative disorders: a comprehensive review. <i>Therapeutic Advances in Hematology</i> , <b>2022</b> , 13, 204062072210939	5.7	1
11	Relapse of liver amyloidosis 6 years after autologous stem cell transplantation. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 926	7.1	O
10	Leukocytosis: the mysteries within. American Journal of Hematology, 2012, 87, 197	7.1	
9	Leukemic phase of Burkitt lymphoma. <i>Blood</i> , <b>2012</b> , 120, 247	2.2	
8	Paraneoplastic syndromes associated to Hodgkinla lymphoma. BMJ Case Reports, 2011, 2011,	0.9	
7	Blue sclerae. JAMA - Journal of the American Medical Association, 2012, 307, 1310-1	27.4	
6	Familial history of bone tumors. JAMA - Journal of the American Medical Association, 2012, 308, 1476-7	27.4	
5	A pain in the neck. JAMA - Journal of the American Medical Association, 2012, 308, 182-3	27.4	
4	The Significance of Hepatic Iron Overload in Allogenic Stem Cell Transplant Recipients <i>Blood</i> , <b>2009</b> , 114, 4313-4313	2.2	
3	The Role of Digital Tomosynthesis In the Staging of Newly Diagnosed Multiple Myeloma: Preliminary Data. <i>Blood</i> , <b>2010</b> , 116, 4057-4057	2.2	
2	Risk of Venous Thromboembolism in Patients with Myelodysplatic Syndrome. <i>Blood</i> , <b>2011</b> , 118, 5245-52	2452	
1	Impact of the Approval of Eculizumab by the Food and Drug Administration on the Frequency of Patients Screened for Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , <b>2011</b> , 118, 4377-4377	2.2	